Sernova (SVA) Stock Price, News & Analysis

Company Overview

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.

Key Stats

• Today's Range: C$0.15 to C$0.16
• 50-Day Range: C$0.15 to C$0.22
• 52-Week Range: C$0.15 to C$0.60
• Volume: 49,850 shs
• Average Volume: 148,865 shs
• Market Capitalization: C$52.16 million
• P/E Ratio: N/A
• Dividend Yield: 7.86%
• Price Target: C$1.83
• Consensus Rating: Buy

Sernova Stock Analysis - MarketRank™

Sernova scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Sernova has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Sernova has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sernova is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sernova is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for SVA.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

Sernova is a leading dividend payer. It pays a dividend yield of 7.86%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Sernova does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for SVA.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Sentiment

Sernova has a news sentiment score of -0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Sernova this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sernova insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.13% of the stock of Sernova is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.05% of the stock of Sernova is held by institutions.

SVA Stock Analysis - Frequently Asked Questions

How have SVA shares performed this year?

Sernova's stock was trading at C$0.23 at the start of the year. Since then, SVA shares have decreased by 31.1% and is now trading at C$0.16.
View the best growth stocks for 2025 here.

How do I buy shares of Sernova?

Shares of SVA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Sernova own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sernova investors own include ARC Resources (ARX), Meta Platforms (META), Newron Pharmaceuticals (NWPHF), Sernova (SEOVF), AMC Entertainment (AMC), Advanced Micro Devices (AMD) and CloudMD Software & Services (DOC).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: TSE:SVA
• CIK: N/A
• Web: www.sinovacbio.com
• Phone: 861082890088
• Fax: N/A
• Employees: 1,959
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: C$1.83
• High Stock Price Target: C$2.50
• Low Stock Price Target: C$1.50
• Potential Upside/Downside: +1,082.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): C($0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-35,698,842.53
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: 473.85%
• Return on Assets: -119.26%

Debt

• Debt-to-Equity Ratio: -4.40
• Current Ratio: 0.32
• Quick Ratio: 18.11

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.03 per share
• Price / Cash Flow: 6.15
• Book Value: C($0.04) per share
• Price / Book: -3.63

Miscellaneous

• Outstanding Shares: 336,496,829
• Free Float: N/A
• Market Cap: C$52.16 million
• Optionable: Not Optionable
• Beta: 1.35